Venetoclax added to dose-adjusted EPOCH-R for newly diagnosed double-hit lymphomas: phase 2 results from ALLIANCE A051701, an open-label, randomised, controlled, phase 2-3 trial.
Abramson JS, Geyer S, Giri S, Pederson L, Hudson A, Hsi ED, Mehta-Shah N, Reagan PM, Deming RL, Little RF, Gore S, Dinner SN, Vallurupalli A, Landsburg DJ, Kahl B, Friedberg JW, Bartlett NL, Leonard JP
Fixed-duration pirtobrutinib plus venetoclax-rituximab versus venetoclax-rituximab for patients with previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (BRUIN CLL-322): an open-label, multicentre, randomised, controlled, phase 3 trial.
Davids MS, Eyre TA, Woyach JA, Roeker LE, Ferrajoli A, Wang Y, Tam CS, Jurczak W, Zinzani PL, Šimkovič M, Li JY, Bosch F, Roos-Weil D, Cramer P, Osterborg A, Islam P, Jacobs R, Skarbnik A, Bhat SA, Kang S, Chen M, Nguyen B, McNeely SC, Chung KL, Oliveira JM, Ito R, Ghia P, Wierda WG
Tertiary lymphoid structures harbour stem-like tumour-specific T cells.
Afeyan AB, Nagler A, Tu CR, Roberti De Oliveira G, Simsek B, Seager MD, El Ahmar N, Sax HE, Lin E, Sud A, Borji M, Forman C, Liu S, Ott PA, Choueiri TK, Abelin JG, Burack R, Li S, Livak KJ, Tyekucheva S, Keskin DB, Chen F, Atkins MB, Simon JM, Signoretti S, Oliveira G, Braun DA, Wu CJ
Single-nucleus multimodal spatial transcriptomics reveals spatial colocalization of neoantigen-expressing tumor cells and cognate T cells.
Nagler A, Sud A, Ghannam JY, Pomerance L, Robles-Oteiza C, Afeyan AB, Weir JA, Russell AJC, Lu WS, Van Orden M, Sonnenholzner A, Marrero GJ, Gong Q, Kumar V, Huang K, Tu C, Lin E, Shim B, De Oliveira GR, Sellars MC, Yoon CH, Reardon DA, Choueiri TK, Olsen LR, Signoretti S, Ott PA, Braun DA, Oliveira G, Li S, Livak KJ, Hacohen N, Chen F, Wu CJ
WNK2 oncogenicity revealed by the discovery and functional characterization of novel gene isoforms in MYD88 mutated Waldenström's Macroglobulinemia.
Guerrera ML, Liu X, Tsakmaklis N, Peachey AL, Kofides A, Hatcher J, Ramirez Gamero A, Guijosa A, Yang G, Sun H, Liu S, Patterson CJ, Meid K, Flynn C, Carrasco RD, Branagan AR, Sarosiek SR, Castillo JJ, Anderson KC, Munshi N, Treon SP, Hunter ZR
Tumor transcriptional state predicts survival in immune-checkpoint-blockade-treated glioblastoma.
Ghannam JY, Bryan J, Weiss J, Kovarsky D, Merrell D, Messer C, Schlueter-Kuck K, Fell GG, Lim-Fat MJ, Youssef G, Rahman R, Qin L, Young GS, Janes JT, Van Orden M, Pfaff KL, Gans A, Lin ES, Huang RY, Danysh BP, Parida L, Li S, Wen PY, Chiocca EA, Neuberg D, Ligon KL, Tirosh I, Reardon DA, Getz G, Wu CJ
Efficacy and safety of durcabtagene autoleucel in a phase 1 trial for patients with relapsed/refractory multiple myeloma.
Sperling AS, Derman BA, Nikiforow S, Alonso A, Ikegawa S, Orwitz N, Quinn DS, Pearson D, Bu D, Milanez-Almeida P, Mataraza J, Nadeem O, Liegel J, D'Souza A, Charles A, Credi M, Ritz J, Jakubowiak AJ, De Vita S, Munshi NC
Pharmacological targeting of IRF4 as a therapeutic strategy for multiple myeloma.
Agius MP, Song C, Liu Q, Iemura T, Hevenor L, Payne NC, Pistofidis RS, Pantano L, Zhao H, Seo HS, Heilpern-Mallory D, Heaslip C, Sun ZJ, Bashyal P, Aranha MP, Lightbody E, Mazitschek R, Dhe-Paganon S, Mitsiades CS, Ghobrial IM, Qi J
Ciltacabtagene autoleucel in high-risk smoldering multiple myeloma: the CAR-PRISM phase 2 trial.
Nadeem O, Cordas Dos Santos DM, Nikiforow S, Bosch-Vilaseca A, O'Donnell E, Redd R, DeBraganca KC, Sperling AS, Liu Y, McEntire C, Arters F, O'Donnell C, Kineavy B, Marto M, Bergeron A, Swenson E, McHugh K, Caron A, Berry Q, Wei H, Durlacher E, Grimm E, Corrado F, Bidikian N, Montes de Oca R, Lengil T, De Wiest D, Gervais C, Panaro K, Smith EL, Anderson K, Jacobson C, Munshi NC, Richardson P, Madduri D, Schecter JM, Tendler C, Wildgust MA, Trippa L, Mateos MV, Ritz J, Ghobrial IM
Daratumumab in high-risk MGUS and low-risk smoldering myeloma: results of the Phase II D-PRISM study.
Nadeem O, Aranha MP, Redd RA, Koontz M, Matous JV, Yee AJ, Zonder JA, Kin A, Magidson S, Lightbody ED, Wu T, Chabrun F, Alberge JB, Dutta AK, Perry J, Sturtevant A, Rahmat M, Tsuji J, Davie C, Ricciardi C, Arters F, Marto M, Bergeron A, Rosenblatt J, O'Donnell EK, Mouhieddine TH, Pantano L, Laubach JP, Richardson PG, Getz G, Trippa L, Sklavenitis-Pistofidis R, Ghobrial IM
Linear RAG scanning mediates editing of Igκ variable region repertoires.
Li X, Hu H, Zhang Y, Zhu T, Guan Y, Xu K, Lin X, Hebert C, Batra H, Zhou J, Ba Z, Wesemann DR, Ye AY, Alt FW
Enhanced dynamic risk stratification of smoldering multiple myeloma.
Chabrun F, Schwartz DE, Gentile S, Mai EK, Gupta TR, Perry J, Cordas Dos Santos DM, Hielscher T, Werly A, Schmidt SK, Theodorakakou F, Fotiou D, Liacos CI, Kanellias N, Gisbert NC, Martin-Sanchez E, Termini R, Waldschmidt J, Chavda SJ, Ainley L, Da Vià MC, De Magistris C, Pettine L, Timonian MA, Alberge JB, Patel V, Costello P, Tobia C, Phan S, Lamb J, Silverio MT, Davis M, O'Donnell EK, Marinac CR, Nadeem O, Bolli N, Yong K, Kortüm KM, Einsele H, Mateos MV, Kumar S, San-Miguel JF, Paiva B, Kastritis E, Dimopoulos MA, Raab MS, Trippa L, Ghobrial IM
